{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:59:44Z","timestamp":1648702784278},"reference-count":27,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T00:00:00Z","timestamp":1279584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2010,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI) in the real clinical world.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We compared consecutive patients on oral double AAD (with clopidogrel and aspirin) who underwent PCI (n=207) and patients who were on single AAD and received a second AAD, just prior to PCI, and either high-dose tirofiban or double-bolus eptifibatide (double AAD plus small molecules group, n=666). The primary end point (incidence of composite ischemic events within one year) included death, acute myocardial infarction, unstable angina, stent thrombosis or repeat PCI or coronary bypass surgery (related to the target vessel PCI failure) and was modelled by Cox\u2019s regression.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 89 composite ischemic events: 24 (11.6%) in double AAD alone and 65 (9.8%) in double AAD plus small molecules groups (log-rank test: p=0.36). Incidences by type of ischemic events were similar between the 2 groups. Based on 21 potential covariates fitted simultaneously, adjusted hazard ratios (HR and 95% confidence intervals) showed that age (HR 1.03, 1.01-1.06, p=0.01), diabetes (HR 1.68, 1.01-2.79, p=0.05) and intra aortic balloon pump (HR 5.12, 2.36-11.10, p=0.0001) were significant risk factors whereas thrombolysis by tenecteplase (HR 0.35, 0.13-0.98, p=0.05) and having had hypertension or anti-hypertensive treatment (HR 0.58, 0.36-0.93, p=0.03) were significant protectors for events. Whether small molecules were present provided a non significant additional benefit as compared to double AAD alone (HR 0.83, 0.51-1.36, p=0.46). Pre-PCI CK-MB were not useful to predict events (HR 1.01, 0.99-1.01, p=0.17).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In clinical world patients undergoing PCI (rescue plus primary &lt;13%) while on double AAD, based on clopidogrel plus aspirin, small molecules (tirofiban or eptifibatide) provided no additive long-term protection against the occurrence of composite ischemic events whereas thrombolysis by tenecteplase did.<\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874192401004010151","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T14:31:52Z","timestamp":1281450712000},"page":"151-156","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GPIIb\/IIIa Receptor Antagonism Using Small Molecules Provides no  Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin"],"prefix":"10.2174","volume":"4","author":[{"given":"Michele","family":"Schiariti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Papalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Placido","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Nesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cuturello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bindo","family":"Missiroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Emilio","family":"Puddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","volume":"353","author":"Topol EJ","year":"1999","unstructured":"Topol EJ, Byzova TV. \n                    Plow EF: Platelet IIb-IIIa blockers \n                    Lancet  \n                    1999; \n                    353\n                    : 227-31.","journal-title":"Lancet"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.12.001","volume":"47","author":"Smith SC Jr","year":"2006","unstructured":"Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. \n                    American College of Cardiology\/American Heart Association Task Force on Practice Guidelines; ACC\/AHA\/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. \n                    ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology\/American Heart association Task Force on Practice Guidelines (ACC\/AHA\/SCAI writing Committee to update the 2001 Guidelines for percutaneous coronary intervention) \n                    J Am Coll Cardiol  \n                    2006; \n                    47\n                    : e1-e121.","journal-title":"J Am Coll Cardiol"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner FG","year":"2009","unstructured":"Kushner FG, Hand M, Smith SC Jr, et al. \n                    2009 Focused Updates: ACC\/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline  and 2007 Focused Update) and ACC\/AHA\/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines \n                    J Am Coll Cardiol  \n                    2009; \n                    54\n                    : 2205-41.","journal-title":"J Am Coll Cardiol"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa0808276","volume":"360","author":"Cantor WJ","year":"2009","unstructured":"Cantor WJ, Fitchett D, Borgundvaag B, et al. \n                    TRANFER-AMI Trial Investigators: Routine early angioplasty after fibrimolysis for acute myocardial infarction \n                    N Engl J Med  \n                    2009; \n                    360\n                    : 2705-18.","journal-title":"N Engl J Med"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","volume":"285","author":"O'Shea JC","year":"2001","unstructured":"O'Shea JC, Hafley GE, Greenberg S, et al. \n                    ESPRIT Investigators (Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy trial): Platelet glycoprotein IIb\/IIIa integrilin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial. a randomized controlled trial \n                    JAMA  \n                    2001; \n                    285\n                    : 2468-73.","journal-title":"JAMA"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","volume":"360","author":"Giugliano RP","year":"2009","unstructured":"Giugliano RP, White JA, Bode Ch, et al. \n                    EARLY ACS Investigators: Early versus delayed, provisional eptifibatide in acute coronary syndromes \n                    N Engl J Med  \n                    2009; \n                    360\n                    : 2176-90.","journal-title":"N Engl J Med"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ccd.21773","volume":"73","author":"Marmur JD","year":"2009","unstructured":"Marmur JD, Poludasu S, Lazar J, Cavusoglu E. \n                    Long-term mortality after bolus-only administration of abciximab, eptifibatide, or  tirofiban during percutaneous coronary intervention \n                    Catheter Cardiovasc Interv  \n                    2009; \n                    73\n                    : 214-.","journal-title":"Catheter Cardiovasc Interv"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","volume":"344","author":"Topol EJ","year":"2001","unstructured":"Topol EJ, Moliterno DJ, Herrmann HC, et al. \n                    TARGET Investigators (Do Tirofiban and ReoPro Give Similar Efficacy Trial): Comparison of two glycoproteins IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization \n                    N Engl J Med  \n                    2001; \n                    344\n                    : 1888-94.","journal-title":"N Engl J Med"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","volume":"47","author":"Bolognese L","year":"2006","unstructured":"Bolognese L, Calzini G, Liistro F, et al. \n                    Randomized comparison of upstream tirofiban versus downstream high dose tirofiban or abciximab on tissue level perfusion and troponin release in high risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial \n                    J Am Coll Cardiol  \n                    2006; \n                    47\n                    : 522-8.","journal-title":"J Am Coll Cardiol"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","volume":"299","author":"Valgimigli M","year":"2008","unstructured":"Valgimigli M, Campo G, Percoco G, et al. \n                    MULTISTRATEGY Investigators: Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or  uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial \n                    JAMA  \n                    2008; \n                    299\n                    : 1788-99.","journal-title":"JAMA"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","volume":"35","author":"Bhatt DL","year":"2000","unstructured":"Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. \n                    Abciximab reduces mortality in diabetics following percutaneous coronary intervention \n                    J Am Coll Cardiol  \n                    2000; \n                    35\n                    : 922-8.","journal-title":"J Am Coll Cardiol"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2009.01.053","volume":"53","author":"De Luca G","year":"2009","unstructured":"De Luca G, Ucci G, Cassetti E, Marino P. \n                    Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty \n                    J Am Coll Cardiol  \n                    2009; \n                    53\n                    : 1668-73.","journal-title":"J Am Coll Cardiol"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11096-004-2269-1","volume":"27","author":"Le Pen C","year":"2005","unstructured":"Le Pen C, Lilliu H. \n                    Choice of GPIIb\/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in? \n                    Pharm World Sci  \n                    2005; \n                    27\n                    : 83-91.","journal-title":"Pharm World Sci"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.02.009","volume":"53","author":"Brener SJ","year":"2009","unstructured":"Brener SJ. \n                    The benefits of platelet glycoprotein IIb\/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? \n                    J Am Coll Cardiol  \n                    2009; \n                    53\n                    : 1674-6.","journal-title":"J Am Coll Cardiol"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ccd.21954","volume":"73","author":"Zijlstra F","year":"2009","unstructured":"Zijlstra F. \n                    The benefits and risks of Abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ? \n                    Catheter Cardiovasc Interv  \n                    2009; \n                    73\n                    : 222-3.","journal-title":"Catheter Cardiovasc Interv"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2459\/JCM.0b013e328334c7b9","volume":"11","author":"Schiariti M","year":"2010","unstructured":"Schiariti M, Saladini A, Missiroli B, et al. \n                    Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant\u2019ANna Tirofiban Safety study \n                    J Cardiovasc Med  \n                    2010; \n                    11\n                    : 250-9.","journal-title":"J Cardiovasc Med"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/hc2901.093504","volume":"104","author":"Gilchrist IC","year":"2001","unstructured":"Gilchrist IC, O\u2019Shea JC, Kosoglu T, et al. \n                    Pharmacodynamics and pharmacokynetics of higher-dose, double bolus eptifibatide in percutaneous coronary intervention \n                    Circulation  \n                    2001; \n                    104\n                    : 406-11.","journal-title":"Circulation"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0735-1097(98)00551-8","volume":"33","author":"Tardiff BE","year":"1999","unstructured":"Tardiff BE, Califf RM, Tcheng JE, et al. \n                    Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II \n                    J Am Coll Cardiol  \n                    1999; \n                    33\n                    : 88-96.","journal-title":"J Am Coll Cardiol"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcin.2009.09.002","volume":"2","author":"Lindsey JB","year":"2009","unstructured":"Lindsey JB, Marso SP, Pencina M, et al. \n                    EVENT Registry Investigators: Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry \n                    J Am Coll Cardiol Intv  \n                    2009; \n                    2\n                    : 1074-82.","journal-title":"J Am Coll Cardiol Intv"},{"key":"refR20","first-page":"166","volume":"3","author":"Puddu PE","year":"2002","unstructured":"Puddu PE, Brancaccio G, Leacche M, et al. \n                    OP-RISK Study Group: Prediction of early and delayed postoperative deaths after coronary artery bypass surgery in Italy. Multivariate prediction based on Cox and logistic models and a chart based on the accelerated failure time model \n                    Ital Heart J  \n                    2002; \n                    3\n                    : 166-81.","journal-title":"Ital Heart J"},{"key":"refR21","doi-asserted-by":"crossref","unstructured":"Miller Ch C III, Reardon MJ, Safi HJ, Eds. \n                    Risk stratification A practical guide for clinicians.  \n                    Cambridge: University Press 2001; pp. \n                    \n                    \n                    1-174.","DOI":"10.1017\/CBO9780511666452"},{"key":"refR22","unstructured":"Menotti A, Puddu PE, Lanti M. \n                    Il rischio in Cardiologia: dalla teoria alla pratica.  \n                    Pavia: Edizioni Internazionali srl 2004; pp. \n                    \n                    \n                    1-189."},{"key":"refR23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","volume":"100","author":"Lotrionte M","year":"2007","unstructured":"Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. \n                    Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention \n                    Am J Cardiol  \n                    2007; \n                    100\n                    : 1199-206.","journal-title":"Am J Cardiol"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"Wiviott SD","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. \n                    TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes \n                    N Engl J Med  \n                    2007; \n                    357\n                    : 2001-15.","journal-title":"N Engl J Med"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott SD","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL, et al. \n                    PRINCIPLE-TIMI 44 Investigators: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial \n                    Circulation  \n                    2007; \n                    116\n                    : 2923-32.","journal-title":"Circulation"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2009.06.021","volume":"54","author":"Dangas G","year":"2009","unstructured":"Dangas G, Mehran R, Guagliumi G, et al. \n                    HORIZONS-AMI Trial Investigators: Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial \n                    J Am Coll Cardiol  \n                    2009; \n                    54\n                    : 1438-46.","journal-title":"J Am Coll Cardiol"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/138945007781386893","volume":"8","author":"Paraskevas KI","year":"2007","unstructured":"Paraskevas KI, Athyros VG, Briana DD, Kakafika AI, Karagiannis A, Mikhailidis DP. \n                    Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures \n                    Curr Drug Targets  \n                    2007; \n                    8\n                    : 942-51.","journal-title":"Curr Drug Targets"}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-151\/TOCMJ-4-151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-151\/TOCMJ-4-151.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-151\/TOCMJ-4-151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:53:03Z","timestamp":1561632783000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/VOLUME\/4\/PAGE\/151\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7,20]]}},"alternative-id":["TOCMJ-4-151"],"URL":"https:\/\/doi.org\/10.2174\/1874192401004010151","relation":{},"ISSN":["1874-1924"],"issn-type":[{"value":"1874-1924","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-5-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-5-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-5-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-7-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}